header logo image


Page 499«..1020..498499500501..510520..»

Letters to the Editor: July 3, 2020 – West Hawaii Today

July 3rd, 2020 8:42 pm

Take your own logic medicine

If I were to write a character for a play, and I had him say in his dialogue phrases such as Must I remind you and Use a little bit of logic to someone he disagrees with (as in Barry Willis letter on Tuesday, June 23), you might comprehend that this character is arrogant and condescending. If I had him use easily debunked propagandistic facts about Trumps accomplishments, you will surmise that this character is loyal to the point of blindness to his idols faults. If you add in his dialogue, a reference to Obamas travel expenses, especially his golf trips, and not even compare that to Trumps, which not only exceeds Obamas, but also enriches the Trump business, then you do get a sense that this character is not applying logic as he implores others to do. I can imagine that he will not respond with calm to this critique, but if he miraculously does, I would hope that he will take his own medicine and apply logic, fact-checking, and self-reflection in examining his conclusions about his idol. Since I am the playwright, that would be the happy ending I would write.

Diane Aoki

Kealakekua

Thinking ahead

If Ironman is to be held in February, it will be during our snowbird season, and our athletes will have an almost impossible task finding accommodation.

I wonder whether it would be possible to create an Athletes Village of some kind. Building could start now, and would provide basic living conditions for a large number of the incoming crowd. After Ironman, this facility could be used to help house our homeless, or less advantaged population.

Judith Orlopp

Kailua-Kona=

Letters policy

Letters to the editor should be 300 words or less and will be edited for style and grammar. Longer viewpoint guest columns may not exceed 800 words. Submit online at http://www.westhawaiitoday.com/?p=118321, via email to letters@westhawaiitoday.com or address them to:

Editor

West Hawaii Today

PO Box 789

Kailua-Kona, HI 96745

Read more:
Letters to the Editor: July 3, 2020 - West Hawaii Today

Read More...

When hope is all there is – The Herald

July 3rd, 2020 8:42 pm

The Herald

Veronica Gwaze

AT some point, 21-year-old visually impaired Milton Kanyenze thought the world around him had collapsed. He was on the verge of giving up.

Life for the then Herbert Chitepo Secondary (HCS) student seemed to be characterized by a frustrating series of one challenge after another.

The HCS ordinary level student had been a soccer, volleyball and chess player before his life took a devastating twist.

Being brought up by unemployed parents who survive on menial jobs to feed the family, Kanyenze looked forward to helping his parents through sport. But as it would, fate appeared to have determined a different trajectory.

His sporting journey began when he was still in Grade 4. Then in 2014 it was abruptly halted by the onset of blindness.

At first it was my left eye. I would tell my parents and friends that I could no longer see but none of them took me seriously, he explained last week.

Maybe it is because I could still do everything by myself and at that stage I even did not take it too seriously. So they must have thought it was one of those attention-seeking teenage stories.

By that time, he was already the school senior soccer teams first choice goal keeper.

Despite his condition, Kanyenze continued his sporting activities. It had become a passion and he could not contemplate abandoning the one thing he thought would deliver his family out of poverty.

He remembers his last match before blindness grounded him for good.

When the opponents discovered that he was blind in one eye, they nicknamed him kondo (the hammerkop).

With brown plumage and a head that looks like a hammer hence its name the hammerkop is a distinctive bird. Hammerkops are the smallest of the African stork. Superstition has it that Hammerkops are bad omens, and it is considered bad luck to harm them. It is partly this superstition that has kept the birds somewhat protected.

There has been a general debate with others claiming that the hammerkop is one eyed hence his nickname. Zoologists, however, maintain that the bird has two eyes.

I was heartbroken; I remember crying during the game that was to be my last match. I gave up.

However, the worst was yet to come.

Three months later, the other eye also lost sight completely, eventually forcing him to drop out of school.

Due to poverty, it took time for his parents to take him to Parirenyatwa Hospital for consultations and seek medical help.

After detecting cataracts in both his eyes, he was referred to an eye specialist in Norton.

With his parents failing to afford the bus fare to and from Norton, one of Kanyenzes friends helped him take up menial jobs to raise the money.

He reckons how, during his trip to Norton, he looked forward to coming back home with his eyesight restored.

I felt so crushed when the specialist, after checking my eyes told me that it was too late and that there was no solution to my problem.

The following days were hell and I planned taking my life.

As if someone was sensing something, a well-wisher came forth and offered to take me for rehabilitation at a local centre.

The first month of his six months rehabilitation was tough as he was still processing living with total visual impairment.

It is during the rehabilitation programme that he learnt to do most activities on his own and to read Braille.

After the six months, he stayed at home until last year when he enrolled back at Hebert Chitepo Secondary, but only to be confronted by school fees challenges.

The situation at home became so severe that even his only sibling, Modester, dropped out of school. She is still out of school.

In November, he is set to write his Ordinary Level Examinations, targeting five subjects English Language, Shona, Heritage Studies, Commerce and History.

Due to the Covid-19 induced national lockdown, Kanyenze is home like most other students.

While others are taking to Online lessons and other ways of keeping up, Kanyenze can neither afford Braille textbooks nor a device to access the Internet.

He is going through a tough time and wishes someone could help him with a laptop or smart phone so he can access online lessons as he prepares for his O level examinations.

Finally I managed to go back to school and realizing that sport was a closed chapter for me, I devoted my entire energy to academics but Covid-19 brought fresh challenges.

I am techno-savvy. I know how to use computers. So if I can get one, I know I will be able to study and cover up for lost time as I look forward to writing my examinations, he said last week.

Kanyenze is not alone in this situation. Most blind students find themselves in the same situation as Braille textbooks are very expensive, making it difficult for one to afford a personal copy.

Read this article:
When hope is all there is - The Herald

Read More...

How to spot toxic plant which causes horrific blisters and blindness – Liverpool Echo

July 3rd, 2020 8:42 pm

Fears were raised after reports a weed resembling a toxic plant which causes blistering and blindness was found in Merseyside this week.

Sefton Council said they received a report that a dangerous plant called giant hogweed had been found on the Trans Pennine Trail which runs through parts of Merseyside.

The scenic route runs coast to coast between Southport and Hornsea in Yorkshire and is a popular route with walkers and cyclists.

Bosses of the route tweeted on Monday that part of the trail from Meadway in Maghull to Chapel Lane, Maghull would be closed for three weeks.

The precaution was in place as giant hogweed - which tends to flower in June and July - can cause horrific blisters, burns and potential blindness if touched.

Walkers were initially told to follow a diversion route that was put in place and other users such as cyclists were advised to find an alternative route while an investigation was taking place.

But, a spokesperson at Sefton Council said the investigation concluded the plant was not giant hogweed and the path was re-opened.

A spokesperson for Sefton Council said: After receiving a report of giant hogweed on the Trans Pennine Trail by Meadway, the council undertook an initial inspection and identified vegetation resembling the plant.

The section of the trail was temporarily closed and a full inspection carried out, which concluded that the vegetation in question was not giant hogweed.

The path was subsequently re-opened.

Find out what is happening in your area by entering your postcode below

Due to the plant looking relatively attractive, it is sometimes difficult to know it is a highly-dangerous weed.

So to keep safe, we have put together some advice on what the plant looks like, what to do if you touch it and how to report it:

What is giant hogweed and how can you protect yourself if you come across it?

Giant hogweed, or Heracleum mantegazzianum, is a weed which has dangerous effects on human health, particularly children.

It was billed "the most dangerous plant in Britain" according to Mike Duddy, senior project manager at Mersey River Trust, due to the damage it can cause.

The toxic weed can grow to more than five metres (16ft) and is widespread along riverbanks, footpaths and canal towpaths, but can also found in any green space.

Its sap contains toxic chemicals which react with light when in contact with human skin, causing horrifying blistering within 48 hours even when lightly touched.

Effectively it prevents the skin from protecting itself from sunlight, and children are the most sensitive to it.

Chemicals from the plant can even get into the nucleus of certain cells causing damage to DNA.

It can also cause blindness if in contact with the eyes.

The plant produces white or slightly-pink flower clusters in an umbrella-shaped head which doesn't make it look particularly dangerous.

The stems are hollow and green with purple blotches and stiff white hairs, and the leaves resemble those of the rhubarb plant, with "irregular and very sharp or jagged edges".

The plant tends to be in flower through June and July.

What are the side effects?

If exposed to the plant it can cause blistering consistent with a chemical burn and can form deep-coloured scars that can last for years.

Being exposed to the sap can also make your skin extremely sensitive to sunlight, meaning blistering could recur over months and even years after your first exposure.

If the sap gets into your eyes it can also lead to blindness.

What to do if you come into contact with hogweed?

The NHS advise that if you touch a giant hogweed, you should cover the affected area and wash it with soap and water, or see a doctor if you develop a reaction.

How can I get rid of giant hogweed?

The Royal Horticulture Society (RHS) advises caution when removing the plant and warns people to cover their arms and legs and ideally wear a face mask when working on it.

It added that local authorities will often take action to remove infestations in a public area.

Cut plant debris, contaminated clothing and tools are potentially hazardous too.

Any skin that comes in contact with the plant should be washed immediately.

The RHS also warned people to ensure that contractors working on your land are aware of the risks and know fully how to deal with this weed.

Sefton Council said if the hogweed is at the side of the public highways it will likely to be for the local authority to treat.

On their website, Sefton Council said: "If the hogweed is at the side of the public highways it will likely to be for Sefton to maintain (treat) so please let us know via the contact centre 0345 140 0845."

The Wildlife and Countryside Act 1981 made it illegal to plant or cause giant hogweed to grow in the wild.

Giant hogweed clearances are carried out to remove the plant.

Here is the original post:
How to spot toxic plant which causes horrific blisters and blindness - Liverpool Echo

Read More...

Bolton’s real shocker: That someone with his bad judgment and moral blindness got anywhere near the White House – Mondoweiss

July 3rd, 2020 8:42 pm

THE ROOM WHERE IT HAPPENEDA White House Memoir by John Bolton

577 pp., Simon & Schuster, $32.50

This book review follows an earlier post I did on Middle East policy in Boltons book.

John Boltons memoir proves that hes a worse human being than Donald Trump most clearly when he describes what happened after Iran shot down an unmanned U.S. drone aircraft over the Straits of Hormuz in June 2019. Bolton says that he was at first delighted that he (and others) convinced Trump to retaliate by escalating the conflict. He gets Trump to agree to strike three Iranian military facilities, even though, as Bolton writes clinically, the attack would be likely entailing casualties.

But Trump has second thoughts. He learns the air raids might kill 150 people. Bolton quotes Trump directly:

Too many body bags, said Trump. . . Not proportionate. And then: I dont like it. They didnt kill any of our people. I want to stop it. Not a hundred fifty people.

Trump calls off the attack. Bolton says, This was the most irrational thing I ever witnessed any president do, and nearly resigns. And three months later, he is gone.

That Bolton thinks this episode shows Trump in a bad light is shocking. The real question is: How did someone with Boltons poor judgment and immoral ethics get into the rooms at the White House where he could help decide if America goes to war?

John Bolton is a corporate lawyer. He speaks no foreign languages, has never lived overseas, and has no expertise in any area of the world. In the 1960s, when he was the prime age to serve in the U.S. military, he got deferments to avoid combat, even though he supported the war in Vietnam. So he has no first-hand experience of what combat is like, although his memoir regularly chides senior U.S. generals with excessive timidity. He served in two national security posts in the George W. Bush administration, from where he enthused over the disastrous U.S. invasion of Iraq in 2003, but his memoir barely mentions the American war there, now in its 18th year.

Boltons book is filled with errors of simple fact. In his chapter recounting the Trump administrations bumbling efforts to overthrow Venezuelas government, he alleges that regime change there should have come earlier, because there is a two-decade-long history of missed opportunities in Venezuela, given the widespread strongly held opposition to the Chavez-Maduro regime. His ignorance is breathtaking. Even critics recognize that Huge Chavez was widely popular for years, and that his successor maintained considerable support up until 2016 or so.

But Boltons misinformation is worse than immoral; it is dangerously stupid, and nowhere more clearly than in his zeal to attack Iran. He still believes Irans leaders are dominated by religious fanaticism, claiming that after forty years, the fervor of Irans Islamic Revolution showed no signs of abating in its political and military leaders. No genuine expert believes this, recognizing that Irans leaders have stayed in power for four decades not because they are impetuous zealots, but instead because they are intelligent, calculating and patient.

Bolton simply takes as a self-evident truth that Iran threatens U.S. national security, and doesnt even stir himself to offer proof. The fact is: Iran has not directly attacked the U.S. since the 1980s. By contrast, Bolton also just assumes that Saudi Arabia is our friend and ally, even though high officials in the desert kingdom arguably had links to the terrorists who destroyed the World Trade Center in 2001 and killed 3000 Americans.

Bolton is proud that within a month of becoming national security adviser he helped convince Trump to shred Obamas 2015 Iran nuclear deal. But Bolton wants more: only full-out regime change would ultimately prevent Iran from possessing nuclear weapons. Here hes even going beyond his notorious New York Times opinion article (To Stop Irans Bomb, Bomb Iran), in which he limited his bellicosity to air strikes against the countrys nuclear installations.

Lets set aside whether Boltons warmongering about regime change is immoral, and quite possibly would break the international laws that prohibit launching wars of aggression. Whats worse, he is colossally stupid. Even assuming Irans present government fell, what does he think would succeed it? A pro-western democracy, delighted to make friends with the U.S.? The same America that supported Saddam Husseins invasion of their country in the 1980s, in which 1 million Iranians died; the same America that waged decades of economic warfare against them, including blocking medical aid as the coronavirus hit; the same America that just 6 months ago assassinated the respected Iranian general, Qasem Soleimani, whose funeral attracted millions of mourners?

Iran has 82 million people, more than twice as many as Iraq, pride in its nationality and culture, and an army whose senior commanders have plenty of combat experience. Bolton and other regime-change advocates simply do not understand the power of nationalism. You can vigorously oppose your government, but join together and fight if your country is under attack. Bolton has learned nothing from the U.S. invasion of Iraq, where resistance started within months, including from people who hated Saddam Hussein. If the U.S. invaded Iran, how many decades into the future would America, and American citizens, suffer retaliation from patriotic Iranians?

Weve already looked at one partial explanation for John Boltons stupidity; he supports Israel and wrongly views its national security as identical to Americas. Unlike the U.S., Benjamin Netanyahus Israel most definitely does have something to fear from Iran. Egypt, Saudi Arabia and the other Gulf states have abandoned the Palestinians and made de facto peace with Israel, at least for now, but Teheran continues to support two independent armed forces in the area: Hezbollah in Lebanon, and Hamas in besieged Gaza. If Israel could neutralize those two forces, it could annex even more than the 30 percent of the West Bank proposed in the Trump peace plan, and strengthen its illegal occupation even further.

(In passing, Boltons reflexive pro-Israel view is an oddity for a man who considers himself a conservative, America first nationalist. Why is he willing, even eager, to fight Israels battles for it by ordering American troops to invade a country that does not threaten us?)

The first press reports about John Boltons memoir were somewhat misleading. His evidence that Donald Trump puts his own re-election considerations before the U.S. national interest is actually a small part of this long book, confined to the last 50 pages or so. Boltons information is useful, but not much of a surprise.

What is truly frightening, though, is what Bolton tells us about himself, and by extension about certain other high-ranking U.S. officials. His real revelation is that even more than we feared, our foreign policy is guided by people who make life-and-death decisions based on a lethal combination of arrogance and ignorance.

More:
Bolton's real shocker: That someone with his bad judgment and moral blindness got anywhere near the White House - Mondoweiss

Read More...

How is technology used to develop cures in 2020? – Wakefield Express

July 3rd, 2020 8:42 pm

Charity tries to eliminate blindness

In the medical industry, technology is helping a lot, from speeding up processes to diagnosing illnesses, carrying out procedures, developing cures and more. So how can technology be used to develop cures?

One of the ways that technology can be used to develop cures in 2020 is by carrying out research. Research is much easier to store and refer back to now due to the systems that have been developed and implemented. It can take years for a cure to be developed but, thanks to research and stored information from previous cures you might find that new cures could be found a lot faster than they could be in the past.

There are a lot of deadly illnesses that dont have cures yet but, with the way technology is improving, you might find that it could potentially be used to find a cure for illnesses like blood disorders, blindness and much more in the medical industry.

Another way that technology can be used to develop cures in 2020 is through the use of Artificial Intelligence AI for short. Artificial Intelligence involves the use of robots and machinery to operate and carry out tasks that a person would do. AI will be programmed to carry out certain tasks and it can complete them at a fast pace and with persistent accuracy. This means that scientists and medical experts can focus their much-needed attention on other things like finding cures for diseases.

Although medical professionals and scientists will be doing all they can to find cures as fast as possible, a bit of help from the public can go a long way. Technology can be used to set up funding pages and charities where you can donate money to different causes.

One of the pages that you can donate money to is the Tej Kohli Cornea Program which is aiming to eliminate corneal blindness across the globe by 2035.

Corneal blindness is a health condition that affects 1.9 million worldwide so, if there is a cure found in the next few years, a lot of people won't have to suffer from this illness anymore.

With technology becoming more advanced, through time, you can expect some more great things to be achieved. Find out more online.

Originally posted here:
How is technology used to develop cures in 2020? - Wakefield Express

Read More...

Letter: Bury the monster – The Manchester Journal

July 3rd, 2020 8:42 pm

To the Editor:

At our southern borders, Donald Trump separates little children from their parents, and confines them to sub-par facilities where several die. He ignores, dismisses, and refuses to take the remedial national action needed such as shutting down businesses in order to confine the national COVID-19 epidemic that's killing thousands of people. Thus, over the lives of people, he favors a robust economy that may in his eyes help get him reelected. He initiates a law suit intended to deprive millions of people of the healthcare they desperately need. He tries to build a wall that will prevent thousands of endangered people from finding refuge in the U.S., that has as our Statue of Liberty declares historically been the safe haven for the oppressed.

What, but an utter incapacity to love, could prompt these attitudes and actions? What but pure hatred feeds Trump's viscous racism implicit in his condoning of white supremacists? And what more than lovelessness denotes a miscreant? Even more distressing, what primitive blindness prevents so many Americans from seeing the Minotaur right before their eyes the conscienceless monster determined to devour them so that he can feed himself? And Donald Trump is indeed conscienceless, being a sociopath incapable of love or empathy, as proven by his actions.

His ascendency to presidential power through democratic process tempts a lapse into misanthropy. But that would not only be unfair, but incorrect: Since we descended from the trees, homo sapiens has been on a developmental continuum, with some segments being less developed than others. This development seems best measured by the capacity to love, which, in turn, manifests itself in an increased value of life. It was not that long ago, in broader historical terms, that the highly civilized society that gave us Virgil and Horace took pleasure in seeing two gladiators trying to kill each other a Roman spectacle that would horrify today's audiences. And it was only a few decades ago that capital punishment now outlawed in most societies and in many of our states was blithely accepted.

With love being the sign of development, it is the less developed among us who see their counterpart in the stunted, loveless Trump. Fortunately, they constitute a minority, Trump having won the presidency though falling three million short in the popular vote. A repeat of this victory is not likely, Trump losing badly in most of today's polling. This is cause for great optimism concerning human development: Love seems to be winning over Trump-promulgated hatred. As Theseus navigated the labyrinth of Crete in order to kill the Minotaur at its center, the people will find their way through the Trump labyrinth of deceit, and bury the monster in the November elections.

Andrew Torre,

Londonderry

Advertisements

If you'd like to leave a comment (or a tip or a question) about this story with the editors, please email us. We also welcome letters to the editor for publication; you can do that by filling out our letters form and submitting it to the newsroom.

The rest is here:
Letter: Bury the monster - The Manchester Journal

Read More...

Goldberg: Trumps re-election message is white grievance – The Mercury News

July 3rd, 2020 8:42 pm

A lot of Republicans are acting puzzled about Donald Trumps re-election pitch. He has no message, one Republican source told Reuters. He needs to articulate why he wants a second term, said another. Some have expressed hope that Trump would find a way to become less polarizing, as if polarization were not the raison dtre of his presidency.

Its hard to know if Republicans like this are truly naive or if theyre just pretending so they dont have to admit what a foul enterprise theyre part of. Because Trump does indeed have a re-election message, a stark and obvious one. It is white power.

The president started this week by tweeting out a video that encapsulates the soul of his movement. In it, a man in The Villages, an affluent Florida retirement community, shouts, White power! at protesters from a golf cart bedecked with Trump signs. Thank you to the great people of The Villages, wrote Trump. Only after several hours and a panic among White House staffers did the president delete the tweet.

His spokesman claimed he hadnt heard his supporters extremely clear words. Trump, naturally, never disavowed them.

And why would he? Republicans might act as if they dont know why Trumps fans are so unfailingly loyal. Some commentators spent the first year or two of his presidency dancing around the reason he was elected, spending so much time probing the economic anxiety of his base that the phrase came to stand for a type of willful political blindness.

But Trump understands that he became a significant political figure by spreading the racist lie that Barack Obama was really born in Kenya. He launched his history-making presidential bid with a speech calling Mexican immigrants rapists and adopted a slogan, America First, previously associated with the raging anti-Semite Charles Lindbergh. Throughout the 2016 campaign, he won the invaluable prize of earned media with escalating racist provocations, which his supporters relished and which captivated cable news.

People voted for Trump for reasons besides racism. There was also sexism. Some voters were just partisan Republicans or thought that reality TV is real and that Trump was as successful as The Apprentice made him seem.

Trump, however, seems to grasp that racism is what put him over the top. Its what made his campaign seem wild and transgressive and hard to look away from.

Now Trumps poll numbers are cratering, we have double-digit unemployment and our pandemic-ravaged nation has been rendered an international pariah. America is faring exactly as well under Trumps leadership as his casinos, airline and scam university did. Its not surprising that hes returning to what he knows and what seemed to work for him before.

In fact, Trump appears to think his problem is that he hasnt been racist enough. On Wednesday, Axios Jonathan Swan reported that Trump regrets listening to his son-in-law Jared Kushners woke ideas as a source put it including on criminal justice reform. Instead, he wants to double down on law and order. He truly believes there is a silent majority out there thats going to come out in droves in November, a source told Swan.

And so last week, as if to prod that silent majority, Trump tweeted out videos of Black people assaulting white people. (Where are the protesters? he asked.) He has made a point of calling the coronavirus the kung flu. At a time when even Mississippi is removing Confederate imagery from its state flag, Trump has thrown himself into the protection of what he calls our heritage.

He signed an executive order directing federal law enforcement to prosecute people who damage federal monuments threatening them with up to 10 years in prison and withholding funds from municipalities that dont protect statues. (Whether this latter provision is enforceable is unclear.) He said hed veto a $741 billion defense bill over a provision, written by Sen. Elizabeth Warren of Massachusetts, requiring that military bases honoring Confederates be renamed. Apoplectic over New York Citys plans to paint the words Black Lives Matter on Fifth Avenue in front of Trump Tower, he called the slogan a symbol of hate.

Polls show that a growing number of them, particularly women, are repelled by Trumps race-baiting and divisiveness. But Republicans who complain that the president is undisciplined, that he cant adhere to a strategy, miss the point: Bigotry has always been the strategy.

The Republicans who support him are yoked to that strategy. Their real frustration isnt that its ugly but that its no longer working.

Michelle Goldberg is a New York Times columnist.

More:
Goldberg: Trumps re-election message is white grievance - The Mercury News

Read More...

Black Lives Matter but Indian lives dont? Our response to violence is double faced – National Herald

July 3rd, 2020 8:42 pm

The ongoing row around online exams for university students is an important example of the discriminatory nature of our social, economic, and educational power structures, which often manifest themselves as caste-blindness and apathy.

Despite UGC guidelines to cancel or postpone the exams, several universities like Delhi Technical University have plans to conduct online exams which will require the students to have access to an internet connection with minimum speed of 1Mbps and a computer with minimum RAM of 2GB, a web-camera, a microphone, and Google Chrome Browser (ver. 75 or above). When Delhi University announced its guidelines for online Open Book Exams in May, a 4G internet connection was on its list of requirements as well.

This is where we must engage in some sociological number crunching.

According to data collected by the National Statistical Office (NSO) in its 75th round (held in 2017-18), only 9 percent households in India have both, a computer at home and an internet connection. While this number is 20% in urban areas, it falls to 4% in rural areas.

Even when the data is adjusted to parse out how many households with students have access to a computer and internet, the number remains stubbornly fixed at 9%.

Within this, the number of Dalit and Adivasi students who have a computer and an internet connection is also just a meager 4%. In states like Jharkhand, Bihar, and Andhra Pradesh, only 5% of all students have a computer and an internet connection. It should be noted that these states have significant Dalit and Adivasi populations and that they routinely feature among the most poverty-stricken states in the country.

The scourge of caste-blindness is such, that the plight of these students didnt even cross the minds of the university administrators who wrote these guidelines that would only benefit the privileged 3% of all students, who unsurprisingly belong to upper caste and upper-class urban backgrounds.

And this is just one type of institutional violence that is inflicted upon students from marginalized communities.

To add insult to the injury, we also trivialise the caste-based oppressions perpetuated by us in everyday life. We call our marginalised folks quota wale, and treat them as talentless slobs in the classroom and greedy opportunists at the workplace. We see reservation as a theft of rights from the hardworking general category students, and we treat our SC/ST/OBC colleagues as inferior and undeserving of promotions and pay raises.

The tragic suicide of Dr. Payal Tadvi is a classic example of this. Incessantly abused and bullied for her caste by three of her upper caste seniors, Dr. Tadvi took her own life last year at the Nair Hospital in Mumbai, where she was pursuing her MD.

Outside of official settings, we hurl casteist slurs at our friends and strangers without knowing what they mean. We make fun of the poor and their ganwaar language. And we filter out specific surnames from lists of applicants, on both LinkedIn and Shaadi.com.

But the great Indian hypocrisy doesnt end with our soulless reactions (or their total absence) to casteism.

Police brutality against George Floyd elicited a very strong and unequivocal condemnation from Indians across the political spectrum. But the wrongful detention of a 27-year-old pregnant student stirred nothing in their hearts simply because her name is Safoora Zargar.

Zargar, who had been an active organizer in last winters anti-CAA and NRC protests was arrested on April 10 in connection with the Jaffrabad road block case (a sit-in protest). Later, she was also charged with the UAPA (Unlawful Activities Prevention Act). She spent over two months in jail before being released on June 24, after her fourth bail application.

Despite applying for bail multiple times in her 75-day ordeal on account of her pregnancy and her increased risk to Covid-19, she was denied each time. Her third bail application was rejected because the judge ruled, When you choose to play with embers, you cannot blame the wind to have carried the spark a bit too far and spread the fire.

On the other hand, Manish Sirohi, a man held for supplying weapons to mobs during the Delhi riots, was granted bail considering the fact that spread of COVID-19 pandemic is on high rise and there is always a risk of the applicant being infected with the said virus in case he is left to be confined in jail.

Arre, hypocrisy ki be seema hoti hai!

Similarly, while Indians publicly mourned the human and animal lives lost in the Australian bushfires last year, far too many laughter emojis were seen all over Indian Facebook when the news of a plane crash in Pakistan came in just days before Eid.

Anguished by this appalling antipathy, my friend Murtaza, a young Pakistani civil servant wrote:-

Aik hi kashti hai, ek hi samandar

Ek hi maazi, haal, bhavishya

Ek hi maslay, saanjhay dukh hain

Phir hinsa, nafrat, daridrata kyun hai?

Kahan hain aman aur usool ke samarthak?

Kahan hain dil ki baat karnay walay?

Kahan hain mulk aur nasl se pehle

Banday to insaan kehne walay?

(We have but one boat and one ocean

A common yesterday, today, and tomorrow

And the same hurts and cruelties of life,

Then why this violence, this hatred, this sorrow?

Where are our pacifists and moralists?

Where are those who talk of love?

And where are those who, before color and creed,

see a fellow person in every human being?)

His words cut me deep and not just because they are so raw. The reflection of the truth in a friends mirror is often sharper than the one in our own.

While hashtags rolled in from Indian netizens for George Floyd, hardly anyone even remembers the name of the Amroha youth who was killed last month. You read his name at the beginning of this article.

Do even you remember it?

Read the original post:
Black Lives Matter but Indian lives dont? Our response to violence is double faced - National Herald

Read More...

Based on distribution channel, the market is segmented into retail stores, e-commerce, clinics and hospitals. Here, e-commerce segment is forecast to…

July 3rd, 2020 8:42 pm

New York, July 03, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "India Vision Care Market By Product Type, By Coating, Lens Material, By Distribution Channel, By Region, Forecast & Opportunities, 2025" - https://www.reportlinker.com/p05916775/?utm_source=GNW

India vision care market is anticipated to record a significant CAGR during the forecast period as growing penetration of electronic items has increased vision related problems in the country.The high levels of pollution in Indian cities is also having a negative impact on peoples eyes.

Other factors contributing to increasing share of India vision care market are technological advances in eye care devices, high expenditure on healthcare and growing awareness among people related to eye health. Efforts from international and national agencies like National Programme for Control of Blindness and Visual Impairment (NPCB&VI) and India Vision Institute (IVI) to raise awareness for eye health and to address vision-related problems is also boosting the vision care products market in India. Moreover, increasing investments in research and development of modern technologies have led to introduction of new products such as contact lenses, intraocular lenses and artificial tears, which is positively influencing the growth of the India vision care market. India vision care market is segmented based on product type, coating, lens material, distribution channel, region and company.Based on product type, the market can be segmented into eyeglasses, contact lens, intraocular lens and others.

Eyeglasses accounted for the lions share in 2019 owing to high demand and lower price when compared with other segments. Based on distribution channel, the market is segmented into retail stores, e-commerce, clinics and hospitals.Here, e-commerce segment is forecast to grow at the highest rate through 2025 as these platforms have variety of options of choose from and discounted price.

Many websites are also introducing online testing where one can check the status of their eyes and take professional advice. Therefore, companies operating in the market are creating online presence to benefit and increase their market share. Major players operating in the India vision care market include Luxottica India Eyewear Pvt Ltd., GKB Rx Lens Pvt. Ltd., Essilor India Private Limited, Carl Zeiss India Pvt Ltd., Bausch & Lomb India Private Limited, Titan Industries Ltd., Auro Laboratories Ltd., Johnson & Johnson Private Limited and others. The market players are constantly making efforts to launch novel products for vision care.

Years considered for this report:

Historical Years: 2015-2018 Base Year: 2019 Estimated Year: 2020 Forecast Period: 20212025

Objective of the Study:

To analyze and forecast the market size of India vision care market. To classify and forecast India vision care market based on product type, coating, lens material, distribution channel, region and company. To identify drivers and challenges for India vision care market. To examine competitive developments such as expansions, new product launches in India vision care market. To conduct pricing analysis for India vision care market. To identify and analyze the profile of leading players operating in India vision care market. The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of manufacturers across the country.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the manufacturers which could not be identified due to the limitations of secondary research. The analyst examined the manufacturers, distribution channels and presence of all major players across India. The analyst calculated the market size of India vision care market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Vision care manufacturers, suppliers, distributors and other stakeholders Government bodies such as regulating authorities and policy makers Organizations, forums and alliances related to vision care Market research and consulting firms The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, India vision care market has been segmented into following categories, in addition to the industry trends which have also been detailed below: Market, By Product Type: o Eyeglasses o Contact Lens o Intraocular Lens o Others Market, By Coating: o Anti-Glare o Anti-reflecting o Others Market, By Lens Material: o Normal Glass o Polycarbonate o Trivex o Others Market, By Distribution Channel: o Retail Stores o E-Commerce o Clinics o Hospitals Market, By Region: o North o South o East o West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in India vision care market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Read the full report: https://www.reportlinker.com/p05916775/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Go here to read the rest:
Based on distribution channel, the market is segmented into retail stores, e-commerce, clinics and hospitals. Here, e-commerce segment is forecast to...

Read More...

Vision Care Market Type, Share Size, Analysis Trends, Demand and Outlook 2028 – 3rd Watch News

July 3rd, 2020 8:42 pm

Vision Care Market: Snapshot

World over, vision care has made some significant advances on the adoption of new population health approaches, especially in developed countries, underpinning the evolution of the vision care market. The goal is to achieve the care paradigm that promotes timely, effective, safe, and equitable treatment. More importantly, vision care must conform to standards of patient-centered care. This entire ecosystem needs to be engendered by standard clinical practice guidelines. Developed markets have been shifting toward the adoption of consistent evidence-based guidelines a key aspect in the expansion of the vision care market. An effective health approach hinges squarely on these evidence-based guidelines. The need has nudged the healthcare industry for increasing the awareness about comprehensive eye examinations in various parts of the world.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4416

Adoption of integrated model of care is a key part of comprehensive eye examinations. These examinations have occupied a key role in the vision care market for detect incipient eye diseases. That aside, such vision care also helps in diagnosing chronic conditions. A case in point is the use of comprehensive eye examinations in detecting multiple sclerosis and diabetes in adult population. Vision screening is different from an eye examination, nonetheless very crucial. In several countries, these screenings have helped identify potential vision problems and facilitate their early treatments. The significance is most evident in community settings. Thus, vision screening is emerging out as a vital diagnostic tool in children in various populations, opening new avenues in the vision care market. In recent years, the proponents of vision care underscore the importance of global partnerships and multisectoral collaboration.

Global Vision Care Market: Overview

An upcoming report on the global vision care market by TMR Research could be a valuable source of information for major stakeholders in the market. The report would offer a brilliant study of the market with its focus on market dynamics, segmentation, and geographical outreach. It could prove to be a useful guideline for players wanting to cement their position in the global vision care market.

Vision care or maintaining eye health are the major concerns globally. Vision-related diseases elevate the risk of blindness or significant vision loss. Good vision eases out daily important activities such as writing, reading, and watching. These also helps in communication, health, work, developmental learning and impacts in overall quality of life. Various factors such as chronic diseases, pollution, and unhealthy diets can affect in functioning of the eyes. Thus, plenty of products and treatments are developed to control vision related problems.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=4416<ype=S

Global Vision Care Market: Trends and Opportunities

Increasing usage of laptops, tablets, PCs, and phones in day-to-day lives, growing older population, and rising number of vision-related problems are believed to be driving the global vision care market. Apart from blindness, there are various vision related problems such as astigmatism, myopia, macular edema, retinal tears, and diabetic retinopathy. Growing demand from the population aged 65+ years, increasing healthcare industry, and rapid technological advancement in eye care products are expected to boost the global vision care market.

Although, declining eye care treatment rate, product design, and brand name are also projected to hinder the growth in the global vision care market. However, growing brand awareness and paradigm shift in the consumer behavior are projected to propel the global vision care market.

Global Vision Care Market: Market Potential

Growing advent of innovative product launches is expected to fuel the global vision care market. There are several products available for vision care such as contact lens, glass lens, contact lens solution, and IOLs. The incorporation of technology in developing vision care products increase efficiency, improves quality and precision of the final product, and reduces overall cost. Increasing demand for restoring normal vision with eyeglasses or contact lenses, cost-effectiveness in using vision care products instead of LASIK eye surgery, and rising advanced medical treatment are believed to be driving the global vision care market.

Global Vision Care Market: Regional Outlook

Region wise, there is a possibility of North America to lead the global vision care market as the region has witnessed rapid development in healthcare industry. Growing population suffering from eye related disorders, rapid technological advancement, and increasing healthcare industry with advanced infrastructure could also be fueling the global vision care market. The prominent countries in this region are US and Canada. Easy availability of glass lens and innovative product launches with the help of modern technology are projected to propel the global vision care market in these countries.

Global Vision Care Market: Competitive Dynamics

Some of the prominent players operating in the global vision care market are Johnson & Johnson, Valeant Pharmaceuticals, Novartis, ZEISS and The Cooper Companies. The upcoming TMR report would provide crucial information on their product offerings, market standing, and strategies for progress.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=4416

See the original post:
Vision Care Market Type, Share Size, Analysis Trends, Demand and Outlook 2028 - 3rd Watch News

Read More...

Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in se…

July 3rd, 2020 8:41 pm

Hansa grants Sarepta exclusive license to develop and promote imlifidase as a potential pre-treatment prior to the administration of gene therapy in Duchenne muscular dystrophy and Limb-girdle muscular dystrophy, for patients with neutralizing antibodies (NAbs) to adeno-associated virus (AAV).

Under the terms of the license: Hansa will receive a USD 10 million upfront payment and is eligible for up to USD 397.5 million in development, regulatory and sales milestone payments. Hansa will book all sales of imlifidase and would be eligible for royalties in the high single-digits to mid-teens on any gene therapy sales enabled through pre-treatment with imlifidase in NAb-positive patients.

Lund, Sweden July 2, 2020. Hansa Biopharma (Hansa), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced today that it has entered into an agreement with Sarepta Therapeutics Inc. (Sarepta), the leader in precision genetic medicine for rare diseases, through which Sarepta is granted an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD). The pre-treatment is intended for patients with pre-existing neutralizing antibodies (NAb-positive patients) to adeno-associated virus (AAV), the technology that is the basis for Sareptas gene therapy products.

Sarepta will be responsible for conducting pre-clinical and clinical studies with imlifidase and any subsequent regulatory approvals. Sarepta will also be responsible for the promotion of imlifidase as a pre-treatment to Sareptas gene therapies following potential approval.

Under the terms of the agreement, Hansa will receive a USD 10 million upfront payment, and is eligible for a total of up to USD 397.5 million in development, regulatory and sales milestone payments. Hansa will book all sales of imlifidase, and earn high single-digit to mid-teens royalties on Sareptas incremental gene therapy sales when treating NAb-positive patients enabled through pre-treatment with imlifidase.

Sren Tulstrup, President & CEO of Hansa Biopharma comments,We see significant potential for our enzyme technology in the gene therapy space overall, and we are excited to partner with Sarepta, a leading player in the field, to use the unique features of imlifidase to potentially enable gene therapy treatment in patients who today arent eligible for these breakthrough therapies due to pre-existing neutralizing antibodies in two conditionswith a very high unmet medical need.

Doug Ingram, President & CEO, Sarepta Therapeutics said,As we expand our leadership position in genetic medicine and build out our gene therapy engine, one of Sareptas central ambitions is to find scientific solutions that bring our potentially life-saving therapies to the greatest number of the rare disease patients we serve. One of the current limitations of gene therapy is the inability to treat patients who have pre-existing neutralizing antibodies to the AAV vector. While our AAVrh74 vector has been associated with a low screen out rate for neutralizing antibodies, even that low rate is inconsistent with our mission.

In pre-clinical and clinical models, Hansas technology has shown the ability to clear the IgG antibodies that prevent dosing AAV-based gene therapies. If successful, this could offer the potential of extending our gene therapy treatments to DMD and LGMD patients who would otherwise have been denied access due to pre-existing antibodies.

Hansa Biopharma will be hosting a conference call with President & CEO Sren Tulstrup, CSO & COO Christian Kjellman and CFO Donato Spota.

Conference Call Partnership agreement with Sarepta TherapeuticsA conference call will take place July 2nd, 2020 at 10:00am CET. The audio cast will be recorded and subsequently be available on the Hansa website https://hansa.eventcdn.net/202007

Participants dial-in numbersSE: + 46 81 241 09 52UK: + 44 203 769 6819US: + 1 646 787 0157

This is information that HansaBiopharma AB is obliged to makepublic pursuant to the EU MarketAbuse Regulation.

About imlifidaseImlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets IgG and inhibits IgG-mediated immune response. It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020.Hansa has also reached an agreement with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S. and has three ongoing phase 2 trials in autoimmune diseases and post-transplant indications.

About gene therapy and neutralizing antibodiesGene therapy is a growing and revolutionizing treatment technology in which healthy gene sequences are inserted into cells of a patient. The treatments are potentially curative in monogenic diseases like hemophilia and muscular dystrophy through a single dose. Harmless recombinant viruses are used to carry the healthy genes into the cell. Due to the partial viral origin of the gene therapy constructs, a certain subset of patients carry neutralizing anti-AAV antibodies towards gene therapy products, depending on what AAV serotype being used, forming a barrier for treatment eligibility.Antibodies prevent effective transfer of healthy gene sequence and can be a safety concern. Imlifidase as a pre-treatment may have the potential to eliminate neutralizing antibodies prior to gene therapy. Similarly, imlifidase may have the potential to enable any potentially necessary re-dosing of gene therapy for all patients.

About Duchenne Muscular Dystrophy (DMD)Duchenne muscular dystrophy is a rare genetic disease caused by mutation in the DMD gene, encoding for the protein dystrophin. Duchenne is an irreversible, progressive disease that causes the muscles in the body to become weak and damaged over time. It is eventually fatal and there is no cure. DMD affects one in 3,500 to 5,000 males born worldwide (approximately 400-500 annual cases in the US) and causes muscles in the body to become weak and most patients use wheelchair by the age of 12.

About Limb-Girdle Muscular Dystrophy (LGMD)Limb-girdle muscular dystrophy or (LGMD) is a genetically and clinically heterogeneous group of rare muscular dystrophies. It is characterised by progressive muscle wasting which affects predominantly hip and shoulder muscles. LGMD has an autosomal pattern of inheritance and currently has no known cure or treatment. It can be caused by a single gene defect that affects specific proteins within the muscle cell, including those responsible for keeping the muscle membrane intact. LGMD has a global prevalence of approximately 1.63 per 100,000 individuals worldwide.

For further information, please contact:Klaus Sindahl, Head of Investor RelationsHansa Biopharma Mobile: +46 (0) 709-298 269E-mail: klaus.sindahl@hansabiopharma.com

About Hansa BiopharmaHansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.The Companys lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. Hansas research and development program is advancing the next generation of the Companys technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.

Go here to see the original:
Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in se...

Read More...

The Future of Medicine Is Bespoke – Fair Observer

July 3rd, 2020 8:41 pm

There was a time when modern medicine was primitive. There were no antibiotics, so every infection took its own course, leading to decline in health. Hypertension and diabetes were largely untreatable. X-ray was new, and remedies had changed but little from medieval times. No one ever embarked on the goodness of preventative treatment, not to speak of predictive medicine, beyond taking a distasteful cod liver oil capsule.

During the last hundred years, modern medicine has undergone a sea change. Just think of it an ever-expanding repertoire of medicines, high-tech procedures, therapies and reams of clinical data to employ when one gets sick. Yet modern medicine remained (in)complete, notwithstanding the therapeutic advances.

READ MORE

Things are now changing thanks to the integration of all such advances, from how a persons diet interacts with ones unique genetic profile to how environmental pollutants affect our thinking, not to speak of preventative medical approaches in health and wellness. The bigperestroikahas begun, and it is poised to transform health care for a growing number of people in the near future. Welcome to a whole new world of personalized, bespoke medicine.

Personalized medicine is, in essence, tailored or customized medical treatment. It treats while keeping in mind the unique, individual characteristics of each patient, which are as distinct as ones fingerprint or signature. It also includes scientific breakthroughs in our understanding of how a persons unique molecular and genetic profile makes them susceptible to certain illnesses. Personalized medicine expands our ability to envisage medical treatments that would not only be effective but also safe for each patient while excluding treatments that may not provide useful objectives.

Personalized medicine is, in simple terms, the use of new methods of molecular scrutiny. It is keyed to help better manage a patients illness or their genetic tendency toward a particular illness or a group of diseases. In so doing, it aims to achieve optimal therapeutic outcomes by helping both clinicians and patients choose a disease management approach that is likely to work best in the context of the patients unique genetic and environmental summary. In other words, it allows to accurately diagnose diseases and their sub-types while prescribing the best form and dose of medication most suited to the given patient.

Personalized, or precision, medicine is not rocket science it is, in essence, an extension of certain traditional approaches to understanding and treating disease. What jazzed up the therapeutic fulcrum of personalized medicine are tools that are more precise. This is what also offers clinicians better insights for selecting a treatment protocol based on a patients molecular profile. Such a patient-specific methodology, as has been practiced for long in certain complementary and alternative medical (CAM) or integrative approaches, not only curtails harmful side effects but also leads to more successful outcomes, including reduced costs in comparison to the current trial-and-error approach to treatment, which has distressingly come to the fore during these extraordinary and unprecedented times of COVID-19.

It is still early days, but the fact remains that personalized medicine has changed the old ways of how we all thought about, identified and managed health issues. As personalized medicine increasingly bids fair to an exciting journey in terms of clinical research and patient care, its impact will only further expand our understanding of medical technology.

What personalized medicine has done is bring about a paradigm shift in our thinking about people in general and also specifically. We all vary from one another what we eat, what others eat, how we react to stress or experience health issues when exposed to environmental factors. It is agreed that such variations play a role in health and disease. It is also being incrementally accepted that certain natural variations found in our DNA can influence our risk of developing a certain disease and how well we could respond to a particular medicine.

All of us are unique individuals, perhaps with the exemption of identical twins, albeit the genomes are unique in them, too. While we are genetically similar, there are small differences in our DNA that are unique, which also makes us distinctive in terms of health, disease and our response to certain medicinal treatments.

Personalized medicine is poised to tap natural variations found in our genes that may play a role in our risk of getting or not getting certain illnesses, along with numerous external factors, such as our environment, nutrition and exercise. Variations in DNA can, likewise, lead to differences in how medications are absorbed, metabolized and used by the body. The understanding of such genetic variations and their interactions with environmental factors are elements that will help personalized medicine clinicians to produce better diagnostics and drugs, and select much better treatments and dosages based on individual needs not as just fixing a pill or two, as is the present-day conventional medical practice.

It is established that a majority of genes function precisely as intended. This gives rise to proteins that play a significant role in biological processes while allowing or helping an individual to grow, adapt and live in their environment. It is only in certain unusual situations, such as a single mutated or malfunctioning gene, that our apple cart is disturbed. This leads to distinct genetic diseases or syndromes such as sickle cell anemia and cystic fibrosis. In like manner, multiple genes acting together can impact the development of a host of common and complex diseases, including our response to medications used to treat them.

New advances will revolutionize bespoke medical treatment with the inclusion of drug therapy as well as recommendations for lifestyle changes to manage, delay the onset of disease or reduce its impact. Not surprisingly, the emergence of new diagnostic and prognostic tools has already raised our ability to predict likely outcomes of drug therapy. In like manner, the expanded use of biomarkers biological molecules that are associated with a particular disease state has resulted in more focused and targeted drug development.

Molecular testing is being expansively used today to identify breast cancer and colon cancer patients who are likely to benefit from new treatments and to preempt recurrences. A genetic test for an inherited heart condition is helping clinicians to determine which course of treatment would maximize benefit and minimize serious side effects while bringing about curative outcomes.

Such complexities exist for asthma and other disorders too. This is precisely where molecular analysis of biomarkers can help us to identify sub-types within a disease while enabling the clinician to monitor their progression, select appropriate medication, measure treatment outcomes and patients response. Future advances may make biomarkers and other tools affordable and allow clinicians to screen patients for relevant molecular variations prior to prescribing a particular medication.

It is already clear that personalized medicine promises three strategic benefits. In terms of preventative medicine, personalized medicine will improve the ability to identify which individuals are predisposed to develop a particular condition. A better understanding of genetic variations could also help scientists identify new disease subgroups or their associated molecular pathways and design drugs to target them. This could also help select patients for inclusion, or exclusion, in late-stage clinical trials. Finally, it will allow to work out the best dosage schedule or combination of drugs for each individual patient.

Yet not everything is hunky-dory for personalized medicine. Critics of precision medicine believe that the whole idea is too much of overhyped razzmatazz, among other things. Proponents, however, argue that when it comes to managing our own health, most of us are used to the idea of taking a one-size-fits-all approach be it medicines, supplements, diets and diagnoses. This may be wrong.

What works, as they put it, for one may be a gaffe for another. As the award-winning oncologist and medical technology innovator, Dr. David B. Agus, author of the groundbreaking bookThe End of Illness, puts it, each patients individual risk factors are based on ones DNA, the environment and a preventative lifestyle plan in response. He begins with simple, profound pointers: How is your sense of smell? and Is your ring finger longer than your middle finger? He explains with statistics-backed guidelines that moving and walking regularly is mandatory because exercising and then sitting is equivalent to smoking cigarettes, while eating and sleeping at consistent hours is imperative because irregularity causes inflammation.

The inference is obvious: We should all understand our physiology and quiz doctors with the thorough, exploratory frame of mind of a gadget buyer. This holds the key to making medicine truly personal, more humane, effective and safe while keeping in mind the individual in us all as unique and distinctive, the sum of the whole not just the parts.

The views expressed in this article are the authors own and do not necessarily reflect Fair Observers editorial policy.

Read more:
The Future of Medicine Is Bespoke - Fair Observer

Read More...

Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer – BioSpace

July 3rd, 2020 8:41 pm

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the retirement of Sandy Mahatme, Sareptas executive vice president, chief financial officer and chief business officer, from the company effective July 10, 2020. The company has commenced a search process to identify the future chief financial officer. During the interim period, the finance and accounting functions will report directly to Sareptas Chief Executive Officer, Doug Ingram, and other departments reporting to Mr. Mahatme will be overseen by members of Sareptas executive committee.

The Sarepta from which Sandy retires is a very different one from the organization he joined as our chief financial officer some eight years ago. And the Sarepta of today a financially solid biotechnology organization with perhaps the industrys deepest and most valuable pipeline of genetic medicine candidates with the potential to extend and improve lives would not have been possible without Sandys business acumen and dedication, said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. On behalf of our board of directors and the entire organization, I want to wish Sandy all the best in his next journey and thank him for his invaluable and numerous contributions to our success and for having built a strong team of finance leaders who will continue to perform as he departs.

Said Mr. Mahatme, It has been a privilege to serve as Sareptas CFO and CBO for almost eight years and to have participated in its remarkable transformation and extraordinary growth. Working with this leadership team and our talented colleagues, we have built a strong foundation for Sareptas ongoing success in achieving its goal of changing the lives of patients with rare diseases around the world. Having built a strong team of finance, IT, facilities, manufacturing and business development professionals, I feel confident that this is a good time to transition to other opportunities, knowing that Sarepta is well-positioned to continue to lead the industry.

Sandy will continue to serve on the Board of Directors for Flexion Therapeutics, Inc., Aeglea BioTherapeutics, Inc., and Idorsia Pharmaceuticals Ltd.

AboutSarepta TherapeuticsAt Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Forward-Looking StatementThis press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the search process to identify the future chief financial officer, the reporting structure during the interim period and the performance of the finance team; Sareptas potential to extend and improve lives; Sareptas goal of changing the lives of patients with rare diseases around the world; and Sarepta being well-positioned to continue to lead the industry.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sareptas control. Known risk factors include, among others: Sarepta may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its product candidates to market, due to a variety of reasons, many of which may be outside of Sareptas control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sareptas product candidates and the COVID-19 pandemic; and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10-K for the year ended December 31, 2019, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect Sareptas business, results of operations and the trading price of Sareptas common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Investors:Ian Estepan, 617-274-4052iestepan@sarepta.com

Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com

Read this article:
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer - BioSpace

Read More...

Connection Between Psoriasis and Joint Disease Indicates Early Treatment Can Be Key – AJMC.com Managed Markets Network

July 3rd, 2020 8:41 pm

Researchers identified a protein that can not only worsen skin inflammation but also plays a key role in damaging joints and bones of patients with psoriasis.

Patients with psoriasis show higher rates of diverse comorbid conditions, such as psoriatic arthritis (PsA), which occurs in one-third of patients with psoriasis and can cause severe, disabling joint disease. However, the reason why so many people with psoriasis develop PsA hasnt been clear.

Since the damage that occurs as a result of PsA is irreversible, identifying patients with PsA early, before too much damage is done to bones, tendons, and joints, is an important consideration, researchers noted.

A team led by Case Western Reserve University School of Medicine researchers discovered that normalizing KLK6 can eliminate skin inflammation and reduce the arthritis-like damage.

"To discover that turning down KLK6 eliminated the skin inflammation and even improved the arthritis-like changesthat was unbelievable," Nicole Ward, PhD, the study's principal investigator and a professor of nutrition and dermatology at the medical school, said in a statement. "This suggests that clinicians need to aggressively treat patients with psoriasis to prevent the arthritis changes, which generally occur after the skin disease presents itself. Since the joint and bone damage are largely irreversible in patients, prevention becomes critical."

In previous research, Ward found that the skin of patients with psoriasis had 6 times more KLK6 than normal. In addition, the PAR1 receptor protein, which causes cellular/tissue responses like inflammation when activated, is overproduced in these patients skin and immune cells. The theory that came from these findings was that KLK6 drove inflammation through signaling of PAR1.

In this new study, the researchers overproduced KLK6 through genetic engineering to develop psoriasis-like skin disease. When PAR1 was deleted, there was a reduction in skin inflammation, as well as an improvement in bone and joint problems.

"These findings suggest that chronic inflammation originating in the skin has the capacity to cause distant joint and bone destruction seen in arthritis, according to Ward.

Reference

Billi AC, Ludwig JE, Fritz Y, et al. KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease. J Clin Invest. 2020;130(6):3151-3157. doi:10.1172/JCI133159

View post:
Connection Between Psoriasis and Joint Disease Indicates Early Treatment Can Be Key - AJMC.com Managed Markets Network

Read More...

The rise of AI in medicine – Varsity Online

July 3rd, 2020 8:41 pm

During the coronavirus pandemic, it's unlikely that AI doctors would work at all: the depth of moral decisions that need to be made simply can't be accommodated by a program.Vidal Balielo Jr.

By now, its almost old news that artificial intelligence (AI) will have a transformative role in medicine. Algorithms have the potential to work tirelessly, at faster rates and now with potentially greater accuracy than clinicians.

In 2016, it was predicted that machine learning will displace much of the work of radiologists and anatomical pathologists. In the same year, a University of Toronto professor controversially announced that we should stop training radiologists now. But is it really the beginning of the end for some medical specialties?

AI excels in pattern identification in determining pathologies that look certain ways, according to Elliot Fishman, a radiology and oncology professor at Johns Hopkins University and a key proponent of AI integration into medicine. Ultimately, specialties that rely heavily on visual pattern recognition notably radiology, pathology, and dermatology are those believed to be at the greatest risk. With the advent of virtual primary care services, such as Babylon, General Practice may also have to adapt in the future.

Pattern recognition functions

In January of this year, an article in Nature reported that AI systems outperformed doctors in breast cancer detection. This was carried out by an international team, including researchers from Google Health and Imperial College London on mammograms obtained from almost 29,000 women. Screening mammography currently plays a critical role in early breast cancer detection, ensuring early initiation of treatment and yielding improved patient prognoses. False negatives are a significant problem in mammography. The study found AI use was associated with an absolute reduction of 9.4% and 2.7% reduction in false negatives, in the USA and UK, respectively. Similarly, use of the AI system led to a reduction of 5.7% and 1.2% in the USA and UK respectively for false positives. The study suggested that AI outperformed the six radiologists individually, and was equivalent to the current double-reading system of two doctors currently used in the UK. These developments have already had perceptible consequences in practice: algorithms eliminate the need for a second radiologist when interpreting mammograms. However, critically, one radiologist remains responsible for the diagnosis.

AI can also be deployed to predict the cognitive decline that leads to Alzheimers disease... allowing early intervention and treatment

Earlier studies have also yielded similar results: a 2017 study published in Nature examined the use of algorithms in dermatology. The study, from Stanford University, involved an algorithm developed by computer scientists using an initial database of 130,000 skin disease images. When compared to the success rates of 21 dermatologists, the algorithm was almost equally successful. Likewise, in a study conducted by the European Society for Medical Oncology, it was found that AI exceeded the performance of 58 international dermatologists. A system reliant on a form of machine learning known as Deep Learning Convolutional Neural Network (CNN) missed fewer melanomas (the most lethal form of skin cancer), and misdiagnosed benign moles (or nevi) as malignant less often than the group of dermatologists.

Further applications in medicine

However, the prospects of AI technology extend beyond the clear applications in cancer diagnosis and radiology: recent studies have also demonstrated that AI may be able to detect genetic diseases in infants by rapid whole-genome sequencing and interpretation. Considering that time is critical in treating gravely ill children, such automated techniques can be crucial in diagnosing children who are suspected of having genetic diseases.

In addition, AI can also be deployed to predict the cognitive decline that leads to Alzheimers disease. Such computational models can be highly valuable at the individual level, allowing early intervention and treatment planning. FDA approval has also been granted to a number of companies for such technologies; these include Imagens OsteoDetect, an algorithm intended to aid wrist fracture detection. In addition, algorithms may have functions in other specialties such as anaesthesiology in monitoring and responding to physiological signs.

Limitations of AI

Despite the benefits that AI integration into clinical practice can provide, the technology is not without limitations. Machine learning algorithms are highly dependent on the quality and quantity of the data input, typically requiring millions of observations to function at suitable levels. Biases in data collection can heavily impact performance; for instance, racial or gender representation in the original data set can lead to differences in diagnostic abilities of the system for different groups, consequently leading to disparities in patient outcomes. Considering that certain pathologies, including melanoma, present differently between races and with different incidences, this can often lead to both later diagnoses and poorer outcomes for racial minorities, as found in a number of studies. Volunteer bias of the data collected is also a pertinent consideration; for example, although lactate concentration is a good predictor of death, this is not routinely measured in healthy individuals.

Considering the magnitude of what is at stake raises the question of whether it is appropriate to rely solely on machines without any human input.

Other key problems which may arise include how algorithms overfit predictions based on random errors in the data, resulting in unstable estimates which vary between data samples. In addition, clinicians may take a more cautious approach when making a diagnosis. Therefore, it may appear that a human underperforms compared to an algorithm since their actions may yield a lower accuracy in tumour identification, however this approach could lead to a lower number of critical cases missed.

Ultimately, the tendency for humans to favour propositions given by automated systems over non-automated ones, known as automation bias, may exacerbate these problems.

Attempts to replace GPs with AI have been unsuccessful

The success of AI integration into clinical practice crucially depends on the receptiveness of patients. Babylon, a start-up company based in the UK, was developed to give medical advice to patients using chat services. Although Babylon has been referred to as the biggest disruption in medical practice in years and a game-changer in UK media as quoted on Babylons website it is questionable how successful the service has been so far Babylon has been slow in recruiting patients and this month, it came under fire for data breaches. The fact that patients lose access to their regular GP if they sign up to Babylon is perhaps a key contributing factor for Babylons slow take-off. Therefore, it appears that human contact is highly valued by patients, after all, at least for some medical specialties.

Potential effect of COVID-19

The COVID-19 pandemic, with its requirements for social distancing, could potentially accelerate the use of AI. COVID-related restrictions could change the perception of patients about remote medical consultations, paving the way for increased receptiveness to primary healthcare apps including Babylon. The pandemic has also highlighted the inadequacies in fast internet access throughout the country. This may encourage increased government investment into broadband infrastructure, which may, in turn, facilitate broader penetration of AI technology. The increased pressure on the NHS may also encourage greater use of algorithms to delegate menial tasks as seen in specialties such as radiology already.

The future

AI will likely become an indispensable tool in clinical medicine, facilitating the work of professionals by automating mundane, albeit essential tasks. By reducing the medical workload, this could allow healthcare professionals to dedicate greater efforts to other aspects of their work, including patient interaction. As emphasised by the President of the Royal College of Radiologists, radiologists can instead focus more of their time on interventional radiology and in managing more complex cases to a much greater extent. Indeed, innovation may aid clinicians and augment their decision-making capabilities to improve their efficiency and diagnostic accuracy, however it remains doubtful whether technology can fully replace these roles. After all, considering the magnitude of what is at stake human life raises the question of whether it is appropriate to rely solely on machines without any human input. Therefore, it remains likely that human involvement will need to continue across medical specialties, although this may be in a reduced or adapted form.

Varsity is the independent newspaper for the University of Cambridge, established in its current form in 1947. In order to maintain our editorial independence, our newspaper and news website receives no funding from the University of Cambridge or its constituent Colleges.

We are therefore almost entirely reliant on advertising for funding, and during this unprecedented global crisis, we have a tough few weeks and months ahead.

In spite of this situation, we are going to look at inventive ways to look at serving our readership with digital content for the time being.

Therefore we are asking our readers, if they wish, to make a donation from as little as 1, to help with our running cost at least until we hopefully return to print on 2nd October 2020.

Many thanks, all of us here at Varsity would like to wish you, your friends, families and all of your loved ones a safe and healthy few months ahead.

Read more here:
The rise of AI in medicine - Varsity Online

Read More...

Case Western Reserve University-led team develops new approach to treat certain neurological diseases – Mirage News

July 3rd, 2020 8:41 pm

A team led by Case Western Reserve University medical researchers has developed a potential treatment method for Pelizaeus-Merzbacher disease (PMD), a fatal neurological disorder that produces severe movement, motor and cognitive dysfunction in children. It results from genetic mutations that prevent the body from properly making myelin, the protective insulation around nerve cells.

Paul Tesar, professor of genetics and genome sciences, School of Medicine

Using mouse models, the researchers identified and validated a new treatment target-a toxic protein resulting from the genetic mutation. Next, they successfully used a family of drugs known as ASOs (antisense oligonucleotides) to target the ribonucleic acid (RNA) strands that created the abnormal protein to stop its production. This treatment reduced PMDs hallmark symptoms and extended lifespan, establishing the clinical potential of this approach.

By demonstrating effective delivery of the ASOs to myelin-producing cells in the nervous system, researchers raised the prospect for using this method to treat other myelin disorders that result from dysfunction within these cells, including multiple sclerosis (MS).

Their research was published online July 1 in the journal Nature.

The pre-clinical results were profound. PMD mouse models that typically die within a few weeks of birth were able to live a full lifespan after treatment, said Paul Tesar, principal investigator on the research, a professor in the Department of Genetics and Genome Sciences at the School of Medicine and the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics. Our results open the door for the development of the first treatment for PMD as well as a new therapeutic approach for other myelin disorders.

Study co-authors include an interdisciplinary team of researchers from the medical school, Ionis Pharmaceuticals Inc., a Carlsbad, California-based pioneer developer of RNA-targeted therapies, and Cleveland Clinic. First author Matthew Elitt worked in Tesars lab as a Case Western Reserve medical and graduate student.

PMD is a rare, genetic condition involving the brain and spinal cord that primarily affects boys. Symptoms can appear in early infancy and begin with jerky eye movements and abnormal head movements. Over time, children develop severe muscle weakness and stiffness, cognitive dysfunction, difficulty walking and fail to reach developmental milestones such as speaking. The disease cuts short life-expectancy, and people with the most severe cases die in childhood.

The disease results from errors in a gene called proteolipid protein 1 (PLP1). Normally, this gene produces proteolipid protein (PLP) a major component of myelin, which wraps and insulates nerve fibers to allow proper transmission of electrical signals in the nervous system. But a faulty PLP1 gene produces toxic proteins that kill myelin producing cells and prevent myelin from developing and functioning properly-resulting in the severe neurological dysfunction in PMD patients.

PMD impacts a few thousand people around the world. So far, no therapy has lessened symptoms or extended lifespans.

For nearly a decade, Tesar and his team have worked to better understand and develop new therapies for myelin disorders. They have had a series of successes, and their myelin-regenerating drugs for MS are now in commercial development.

In the current laboratory work, the researchers found that suppressing mutant PLP1 and its toxic protein restored myelin-producing cells, produced functioning myelin, reduced disease symptoms and extended lifespans.

After validating that PLP1 was their therapeutic target, the researchers pursued pre-clinical treatment options. They knew mutations in the PLP1 gene produced faulty RNA strands that, in turn, created the toxic PLP protein.

Additional team members included Lilianne Barbar, Elizabeth Shick, Yuka Maeno-Hikichi, Mayur Madhavan, Kevin Allan, Baraa Nawash, Artur Gevorgyan, Stevephen Hung, Zachary Nevin, Hannah Olsen, Daniela Schlatzer, David LePage, Weihong Jiang and Ronald Conlon from Case Western Reserve University School of Medicine; Berit Powers, Hien Zhao, Adam Swayze and Frank Rigo from Ionis Pharmaceuticals; and Midori Hitomi from Cleveland Clinic.

This research was supported by grants from the National Institutes of Health, New York Stem Cell Foundation and European Leukodystrophy Association. Philanthropic support was provided by the Geller, Goodman, Fakhouri, Long, Matreyak, Peterson and Weidenthal families and the CWRU Research Institute for Childrens Health.

Read more:
Case Western Reserve University-led team develops new approach to treat certain neurological diseases - Mirage News

Read More...

Personalized Cancer Drugs Market Expected to Witness a Sustainable Growth over 2025 – 3rd Watch News

July 3rd, 2020 8:41 pm

Global Personalized Cancer Drugs Market: Snapshot

Genetic sequencing has proven that no two cancer cases are absolutely identical, heavily depending on genetic profiles of the patients, which defines their immunity power. But frequently, several promising pipeline drugs fail to reach the market for not being commonly useful for the masses. In this scenario, a small but increasing number of personalized cancer drugs are allowed by the FDA for the treatment of particular mutations. Nearly one third of cancer drugs are prescribed off-label, as it provides help to the patients immediately. These targeted agents are directed at specific molecular feature of the cancer cells and hence produce greater effectiveness with significantly less toxicity.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=118

The global market for personalized cancer drugs market is gaining traction from increased government support for precision-medicine. For example, in June 2016, the U.S. National Cancer Institutes revealed its plans to enroll thousand patients in a trial called NCI-MATCH, which is aimed at matching patients to twenty possible compounds on the basis of their genetic abnormalities. Along the similar lines, The American Society of Clinical Oncology has also announced a registry termed as TAPUR, collecting data on the fate of patients who receive personalized cancer drugs off-label.

Another factor driving the global personalized cancer drugs market is the falling cost of genetic sequencing, which is enabling the quick approval of drugs for off-label clinical trials on patients in need across the world.

Personalized Cancer Drugs Market: Overview

Personalized drugs, or customized drugs, are tailored to suit the needs of individual patients. Earlier, various patients suffering from the same type of disease were given the similar treatment plan. However, it became evident to physicians that a particular treatment worked differently for different patients, mainly owing to a varied genetic makeup. The concept of personalized medicine is based on the analysis of etiology of disease in individual patients and offers treatment that is more efficient, predictable, and precise.

Cancer is a common chronic disease and a major cause of fatality around the globe. The development of personalized cancer drugs has gained pace as they have relatively fewer side effects compared to standard drugs. Personalized cancer drugs target a specific protein or gene responsible for the growth and survival of a cancer type.

Personalized Cancer Drugs Market: Trends and Opportunities

The personalized cancer drugs market is primarily fueled by the rising prevalence of various cancer types such as lung cancer, breast cancer, prostate cancer, melanoma and leukemia, and colorectal cancer. According to the Surveillance, Epidemiology, and End Results Program sponsored by the National Cancer Institute (NCI), an estimated 13,397,159 people in the United States were affected with various cancer types in 2011. Moreover, in 2014, around 1,666,540 new cancer cases were diagnosed in the country, with nearly 585,720 deaths resulting from cancer. The personalized cancer drugs market is also driven by several advantages associated with this new treatment therapy and ongoing developments in the field of genetic science.

On the flip side, high cost associated with the genetic testing of patients and tumor samples may serve as a growth restraint on the market for personalized cancer drugs. In addition to this, the lack of insurance plans to cover these tests in developing nations of Asia Pacific and Rest of the World hampers the market to some extent. This can be attributed to low per capita income and poor reimbursement scenario.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=118

Personalized Cancer Drugs Market: Geographical Assessment

From a geographical perspective, the personalized cancer drugs market has been broadly segmented into Europe, Asia Pacific, North America, and Rest of the World (RoW). The market for personalized cancer drugs is led by North America. The chief factors responsible for the regions lead position are aggressive research and development activities, technical advancements, higher affordability for expensive treatments and therapies, and greater healthcare awareness. Europe is also a key market for personalized cancer drugs owing to significant funding from several governments and the growing penetration by U.S.-based companies.

Asia Pacific holds immense promise for players in the personalized cancer drugs market, powered mainly by Japan. The regional market is likely to be fueled by the presence of a large pool of cancer patients and improving healthcare infrastructure. The growth of the APAC personalized cancer market can also be attributed to the rapidly evolving medical tourism industry. In the RoW segment, Mexico, Brazil, Russia, and South Africa represent potential markets.

Personalized Cancer Drugs Market: Competitive Landscape

Some of the key players competing in the personalized cancer drugs market are F. Hoffmann-La Roche Ltd., Pfizer Ltd., Cell Therapeutics, Inc., H3 Biomedicine, Inc., bioTheranostics, GlaxoSmithKline, and Abbott Laboratories. Zelboraf (vemurafenib) by F. Hoffmann-La Roche Ltd. and Xalkori (crizotinib) by Pfizer Ltd. are some notable targeted drugs for the treatment of cancer.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/personalized-cancer-drugs-market

Go here to read the rest:
Personalized Cancer Drugs Market Expected to Witness a Sustainable Growth over 2025 - 3rd Watch News

Read More...

Genetically modified mosquitoes could be released in Florida this summer – WFLA

July 2nd, 2020 1:47 pm

(THE CONVERSATION) This summer, for the first time, genetically modified mosquitoes could be released in the U.S.

On May 1, 2020, the company Oxitec received anexperimental use permitfrom the U.S. Environmental Protection Agency to releasemillions of GM mosquitoes(labeled by Oxitec as OX5034) every week over the next two years in Florida and Texas. Females of this mosquito species, Aedes aegypti, transmit dengue, chikungunya, yellow fever and Zika viruses. When these lab-bred GM males are released and mate with wild females, their female offspring die. Continual, large-scale releases of these OX5034 GM males should eventually cause the temporary collapse of a wild population.

However, as vector biologists, geneticists, policy experts and bioethicists, we are concerned that current government oversight and scientific evaluation of GM mosquitoes do not ensure their responsible deployment.

Genetic engineering for disease control

Coral reefs that can withstand rising sea temperatures,American chestnut treesthat can survive blight andmosquitoes that cant spread diseaseare examples of how genetic engineering may transform the natural world.

Genetic engineering offers an unprecedented opportunity for humans to reshape the fundamental structure of the biological world. Yet, as new advances ingenetic decodingandgene editingemerge with speed and enthusiasm, the ecological systems they could alter remain enormously complex and understudied.

Recently, no group of organisms has received more attention for genetic modification than mosquitoes toyield inviable offspringor make themunsuitable for disease transmission. These strategies hold considerable potential benefits for the hundreds of millions of people impacted bymosquito-borne diseaseseach year.

Although the EPA approved the permit for Oxitec, state approval is still required. A previously planned release in the Florida Keys of an earlier version of Oxitecs GM mosquito (OX513) waswithdrawn in 2018aftera referendum in 2016indicated significant opposition from local residents. Oxitec has field-trialed their GM mosquitoes inBrazil, the Cayman Islands, Malaysia and Panama.

Thepublic forumon Oxitecs recent permit application garnered 31,174 comments opposing release and 56 in support. The EPA considered these during their review process.

Time to reassess risk assessment?

However, it is difficult toassess how EPA regulatorsweighed and considered public comments and how much of theevidence used in final risk determinationswas provided solely by the technology developers.

The closed nature of this risk assessment process is concerning to us.

There is a potential bias and conflict of interest when experimental trials and assessments of ecological risk lackpolitical accountabilityand are performed by, or in close collaboration with, the technology developers.

This scenario becomes more troubling with afor-profit technology companywhen cost- and risk-benefit analyses comparing GM mosquitoes to other approachesarent being conducted.

Another concern is thatrisk assessmentstend to focus on only a narrow set of biological parameters such as the potential for the GM mosquito to transmit disease or the potential of the mosquitoes new proteins to trigger an allergic response in people and neglect other importantbiological,ethicalandsocialconsiderations.

To address these shortcomings, the Institute for Sustainability, Energy and Environment at University of Illinois Urbana-Champaign convened a Critical Conversation on GM mosquitoes. The discussion involved 35 participants from academic, government and nonprofit organizations from around the world with expertise in mosquito biology, community engagement and risk assessment.

A primary takeaway from this conversation was an urgent need to make regulatory procedures more transparent, comprehensive and protected from biases and conflicts of interest. In short, we believe it is time to reassess risk assessment for GM mosquitoes. Here are some of the key elements we recommend.

Steps to make risk assessment more open and comprehensive

First, an official, government-funded registry for GM organisms specifically designed to reproduce in the wild and intended for release in the U.S. would make risk assessments more transparent and accountable. Similar to the U.S.database that lists all human clinical trials, this field trial registry would require all technology developers to disclose intentions to release, information on their GM strategy, scale and location of release and intentions for data collection.

This registry could be presented in a way that protects intellectual property rights, just as therapies entering clinical trials are patent-protected in their registry. The GM organism registry would be updated in real time and made fully available to the public.

Second, a broader set of risks needs to be assessed and an evidence base needs to be generated by third-party researchers. Because each GM mosquito is released into a unique environment, risk assessments and experiments prior to and during trial releases should address local effects on the ecosystem and food webs. They should also probe the disease transmission potential of the mosquitos wild counterparts andecological competitors, examine evolutionary pressures on disease agents in the mosquito community andtrack the gene flowbetween GM and wild mosquitoes.

To identify and assess risks, a commitment of funding is necessary. The U.S.EPAs recent announcementthat it would improve general risk assessment analysis for biotechnology products is a good start. But regulatory and funding support for an external advisory committee to review assessments for GM organisms released in the wild is also needed;diverse expertise and local community representationwould secure a more fair and comprehensive assessment.

Furthermore, independent researchers and advisers could help guide what data are collected during trials to reduce uncertainty and inform future large-scale releases and risk assessments.

The objective to reduce or even eliminate mosquito-borne disease is laudable. GM mosquitoes could prove to be an important tool in alleviating global health burdens. However, to ensure their success, we believe that regulatory frameworks for open, comprehensive and participatory decision-making are urgently needed.

This article was updated to correct the date that Oxitec withdrew its OX513 trial application to 2018.

[Deep knowledge, daily.Sign up for The Conversations newsletter.]

This article is republished from The Conversation under a Creative Commons license. Read the original article here:https://theconversation.com/genetically-modified-mosquitoes-could-be-released-in-florida-and-texas-beginning-this-summer-silver-bullet-or-jumping-the-gun-139710.

The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)

Brian Allan,University of Illinois at Urbana-Champaign;Chris Stone,University of Illinois at Urbana-Champaign;Holly Tuten,University of Illinois at Urbana-Champaign;Jennifer Kuzma,North Carolina State University, andNatalie Kofler,University of Illinois at Urbana-Champaign

Read more:
Genetically modified mosquitoes could be released in Florida this summer - WFLA

Read More...

Outlook into the Cell Culture Protein Surface Coating Global Industry to 2025 – Featuring PerkinElmer, Promega & Qiagen Among Others -…

July 2nd, 2020 1:46 pm

DUBLIN--(BUSINESS WIRE)--The "Cell Culture Protein Surface Coating Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global cell culture protein surface coating market is currently experiencing strong growth. Looking forward, the publisher expects the market to grow at a CAGR of around 12% during 2020-2025.

A cell culture protein surface coating helps in enhancing the adhesion and proliferation of different cells, such as leukocytes, neurons, epithelial and fibroblasts, in vitro isolation and cultivation process.

The inner surface of a flask or petri dish is generally coated with extracellular matrix or proteins like laminin, collagen, fibronectin and vitronectin. Cell culture enables researchers to grow animal or plant cells in a favorable artificial environment, which further assists in understanding the roles of proteins in cell attachment, migration and function. It also aids in developing model systems for research, studying cellular functions, stem cell research, drug discovery and genetic engineering.

Owing to the growing prevalence of chronic diseases, the interest of scientists and various biotechnology companies in cancer and stem cell research is escalating around the world. Stem cells are effective in treating cancer, brain diseases, cell deficiency therapy, and cardiovascular diseases. This represents one of the significant factors, which is strengthening the global cell culture protein surface coating market growth.

Apart from this, the adoption of 3D cell cultures has increased in recent years, which has also contributed to market growth. A 3D cell culture refers to a process that assists in growing biological cells in a controlled environment, wherein these cells can interact with their surroundings. Furthermore, inflating income levels and increasing healthcare expenditures are projected to strengthen the market growth in the upcoming years.

Companies Mentioned

Key Questions Answered in this Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Cell Culture Protein Surface Coating Market

5.1 Market Overview

5.2 Market Performance

5.3 Market Forecast

6 Market Breakup by Protein Source

6.1 Animal-derived Protein

6.2 Human-derived Protein

6.3 Synthetic Protein

6.4 Plant-derived Protein

7 Market Breakup by Type of Coating

7.1 Self-Coatings

7.2 Pre-Coatings

8 Market Breakup by Application

8.1 Scientific Research

8.2 Industrial Production

9 Market Breakup by Region

9.1 North America

9.2 Asia Pacific

9.3 Europe

9.4 Latin America

9.5 Middle East and Africa

10 SWOT Analysis

10.1 Overview

10.2 Strengths

10.3 Weaknesses

10.4 Opportunities

10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview

12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Competition

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 Price Indicators

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/v7pik4

Continued here:
Outlook into the Cell Culture Protein Surface Coating Global Industry to 2025 - Featuring PerkinElmer, Promega & Qiagen Among Others -...

Read More...

The Future of Sports – Bleacher Report

July 2nd, 2020 1:46 pm

Each night, around 7 o'clock, I drift off into a little daydream. This has been the case for weeks now. My beloved Mets are jogging onto the grass at Citi Field, taking their positions; their ace, Jacob deGrom, making a beeline to the mound. I am up out of my seat, applauding, gazing out onto the field. I look up to the sky, and that's it, really. The scene tends to slip away from there. I look down to see the gates of my apartment's window guard and the emptied streets of Manhattan beyond them. I really am clapping, but it's got nothing to do with baseball. It's in support of local nurses and doctors at work or changing shifts. Across New York City, this ritual plays out night after night (the clapping for health care workersnot the Mets fantasies, I don't think).

There's a crossing of wires at play, like my precious sports memories are mingling with the signatures of my life during the COVID-19 eraclapping, quarantining, boredom. Will it stay this way? For a while, at least, I think it will.

As MLB, the NBA and other leagues near their returns, I find myself fascinated by questions pertaining to the virus and the ways it will ripple through our leagues. How many players will contract it? How will leagues' models evolve as they move forward? Even for mea lifelong overcommitted fan who sends excessive, neurotic text threads (unresponded to) during regular-season gamesI think most of the drama in sports will come not from daily games but from daily tests results. This is the virus overpowering the once-invincible sports machine.

Already, so much of the mystique of sports has been lost. I miss the steady, circular rhythm of leagues in-season, the way they appeared day after day, overlapping only a few sacred times a year as if choreographed by the moon instead of computers and marketing teams. I miss the shameless self-importance of teams playing no matter what. (Spring training continued for 10 days after the first cases of COVID-19 appeared in Florida.) It was simply more fun back when we could view athletes as impervious superheroes rather than as bored video-gamersor, worse, as medical patients. There is something uncomfortable about having seen a dominant, intimidating player like Rudy Gobert briefly exposed as reckless and unhygienic. Games will return soon enough, but what about the underlying myths that lend them relevance and depth?

The NBA's bubble-based return, set for July 30, cuts against team fandomso driven by proximityby moving everyone to Disney World. It admits that the game could go on without us, the fans, rowdy old faithful, by playing in near silence. Game rules are changing, too, yielding to the virus' demands. There are smaller coaching staffs to protect older people from exposure, and expanded rosters for when the inevitable happens. Every league is making compromises: MLB might ban its most endearing prop, the sunflower seed, and tweak its most fundamental, unique feature, the nine-inning game.

These leagues are right to weigh these measures and to take them. They are preventing tragedies, not creating them. But the bending of tradition makes me wonder about the future of sports, about how things just changed overnight, and how they might change again in 10 years or 50. Maybe that will be the enduring impact of COVID-19 when it comes to sportsthat it opened the gates to change.

Naturally, this is where things get strange. Stick it out anyway. Consider the ways that fans and leagues are already adapting to this odd time, this time of no sports, and then imagine what comes next, and what after that. One small bit of innovation leads to an unpredictable new one, and on it goes. Very quickly, this evolution brings us into the realm of science fiction.

We might be there already. While games were on hold, the public embraced something that in the past seemed both silly and dystopian: game simulations. Las Vegas offered sim-game betting lines; we hosted virtual Madden watch parties right here at B/R. They were and are an obvious placeholder for real sports. Still, their popularity made me curious about their power down the road, if animated graphics improve enough to match real sports. Technologically speaking, could that day be coming? I asked an expert.

Nicholas Bostrom is a professor at Oxford and a pioneer of the simulation theory, which posits that we may be living in a knockoff version of Earth created by a more advanced (real-life) society. (Assuming that computers will someday be able to produce unlimited realistic simulations of life, we might be wise, he suggests, to already "think that we are likely among the simulated minds rather than among the original biological ones.") Bostrom published Are You Living in a Computer Simulation? way back in 2003. Today, few are better equipped to tell us about the future of sims. So, Professor, how good can they get?

"Eventually we will have completely realistic virtual reality simulations that would be indistinguishable from physical reality," he says. "I don't see why in theory you couldn't have a purely artificial creature that was competing against another in a way that would create a sports event."

You might be wondering what the point of this would be once sports return. Well, consider the NBA's most exhausting debate topic: load (or injury) management. Back when there were regularly scheduled games, we wasted much time meditating on the notion of, say, Kawhi Leonard taking a night off, letting his teammates dominate the lowly Cavaliers or Knicks in front of a crowd that paid to see him play. It's obvious that if there were fewer games, the need to skip some of them would decrease. Fewer games would also soothe another of the league's concerns: players' lack of sleep amid a busy travel schedule.

Simulations could merge these issues and resolve them at once. Why not simulate lopsided games like Clippers-Cavs, providing rest for Leonard and everybody else involved? Each year, each team could sim 10 or 12 games, allowing a 70- or 72-game schedule for playersalready a desired ballparkand a full 82-game slate for the league's partners, like TV networks and casinos, who would package the simulated visuals and box scores.

Maybe this idea seems a little far out, but the NBA rarely minds. It is already welcoming the ideas of the future, from the four-point shot to aerospace revolution.

Indeed, Commissioner Adam Silver has long seen supersonic flight as the key to a truly global league. With it, Portland could face Sydney and return four hours later, in time for bed. We already have an Atlantic Division with teams from America's Northeast; how about adding a Transatlantic Division featuring Brazil, Spain and Nigeria? For now, the problem is a logistical one. "Under existing airline technology, the planes aren't fast enough to at least play in the current framework of our regular season," Silver told USA Today in 2017. Fortunately, with help from Elon Musk, Richard Branson and more, supersonic jets are on their way. Just one of many game-changers to come.

Robots have perfected three-point shooting and will someday make flawless floor-spacers. Salaries paid in cryptocurrency will provide a cap loophole and threaten the league's financial structure. Augmented reality on-screen willsomehowincrease complaints about players' shot selection. Advanced tracking through biometric data will grow into a major concern regarding personal privacy. How much should bidding teams know about a free agent's body? Who gets to dictate the right body fat percentage for somebody else or whether a balky ankle is strong enough to play on? And, as the Wall Street Journal once asked: If a fan gains access to a player's medical status and uses it to wager on a game, is that insider trading? (If the answers to these questions seem like a privacy violation, then consider how quickly athletes' COVID-19 test results became expected public information, even though they're irrelevant so long as sports are on hold. If there is already a demand to know whether Ezekiel Elliott, a running back, is experiencing an inability to smell, then there's no doubting the future demand for intimate insight about his legs.)

Yes, the future can seem vast and spookythough not to Thomas Frey. Frey is an author and member of the Association of Professional Futurists. His job is to burst with ideas, and he's bursting all right, riffing on the future of medicine, tech, sports, you name it. He envisions not only the events of the future but also the issues that will counter those eventsthe future's future. "Drone racing is kind of a hot area right now," he says, "but my sense is that the drone racing eventually gets so fast that you can't even see it, and so I'm not sure that sport sticks around." Dang. What else? Frey wants to elevate existing sportsthe ones played on the groundthrough the control and reduction of gravity. (Think NFL meets Quidditch or Slamball with no need for trampolines.) He wonders about anti-aging, tooin this case, what 3,000-year lifespans might mean for athletic primes.

Other revolutions are impossible to imagine playing out (unless you happen to be a member of the APF). "We're close to reviving extinct species like woolly mammoths," Frey notes, before pondering the cruelty of secluding them from other, natural-born animals. An idea strikes him. "Creating a sport with woolly mammoth riders going around the trackthat would seem bizarre today," he says. "But I would definitely pay to go see that."

Of course, there is not only the matter of tweaking (or inventing) sports, but also that of tweaking the players themselves. One of Frey's favorite topics is genetic engineeringthe process of tinkering with human genes before birth. "We're reinventing people. We're making people more durable. We're giving rights to CRISPR [the bio-tech giant], who will give us superbabies who grow up to be superhumans," he says. OK then. Frey thinks it's inevitable that, someday, we'll be able to genetically manufacture superior athletes: bigger, faster, smarterto an uncanny degree. He wonders about "downloading the human brain" and uploading it into the mind of another person. In time, if this all gets easy and silly enough, a supertoddler could have the basketball IQ of LeBron James. (Just imagine the recruiting violations that would follow.)

Bostrom has explored genetic engineering as well. "The enhancement options being discussed," he wrote in 2003, "include radical extension of human health-span, eradication of disease, elimination of unnecessary suffering" and more. A superhuman ability to ward off illnesssay, a coronaviruswould certainly come in handy. So too would advancements that eliminate athletic limitations. Imagine how a perfect set of knees would have changed the careers of Greg Oden, Brandon Roy and others; imagine Shaquille O'Neal with a sprinter's endurance; imagine Jimmer Fredette at 7'3".

Sounds pretty greator actually it sounds like it would look pretty great, visually. But would this be good for sports? Is it ethical? Or the right spirit? And how would this impact the lives of the athletes we love?

Every tech innovation takes something away from the humans it replaces or (ostensibly) aids. Flawless three-and-D bots entering the NBA would not only change the game but also eliminate dozens or hundreds of lucrative jobs. Supersonic travel, alluring as it may be, could have untold effects on passengersespecially international-league athletes, flying overseas day after day. Genetic engineering could draw a devastating, permanent line between the haves and the have-nots.

When it arrives in full force, Frey says, crafting a given attribute"20/10 vision, a perfect heart"may well cost tens of thousands of dollars. There's no telling what else will be at the disposal of fortunate young athletes then (though Frey, of course, has some ideas, including advanced VR headsets).

Already, financial inequality pervades all of sports. Young basketball players need to be able to cover the costs of trainers and AAU travel teams to earn recognition; it's probably not a coincidence that the children of well-off former players are entering the league at a higher rate than ever. Young baseball players need not only training but also equipment, toomitts, balls, bats, helmets, cleats. (Cleveland pitcher Mike Clevinger recently blamed these costs for the sport's declining popularity among young athletes.) Golf, football, hockeyevery major sport operates behind a financial barrier to entry. In 2018, The Atlantic noted that "just 34 percent of children from families earning less than $25,000 played a team sport at least once a day in 2017, versus 69 percent from homes earning more than $100,000." (Those numbers came from a study by the Aspen Institute, which found that the gap was rapidly growing.)

Imagine a world in which the NBA MVP is an 8'6" trust-fund kid. It seems awfully shallow. Could a souped-up superhuman celebrate the award with the same tenderness as Kevin Durant did in 2014? Even if they did, would we bother to cry along with them? There is no great story in sports without long odds and a dash of relatability.Genetic engineering would destroy the enduring notion of the underdog. It would dull the sweetness of our games, the unpredictability, the misery, the reward. What, then, would be left?

"I'm not particularly excited about sports enhancements," Bostrom says, speaking broadly. "We shouldn't make the mistake of thinking everything that makes the sport easier or makes performance better makes the sport more enjoyable. I think we should think of these things more as, You're designing a game. Think creatively about what would make the most fun game. It's not always the easiest thing."

So far, leagues have mostly welcomed new tech as it arrives, a concerning trend. Consider the modern obsession with instant replay.

Think back to the men's NCAA title game last April. With the season on the line, the ball was knocked out of a Texas Tech dribbler's hands and flew out of bounds. For anybody who has ever picked up a basketball and played a game on any level, it was instantly recognizable as Tech's ball. But after several minutes of replaywhich included referee consultant Gene Steratore saying, "At times, guys, I will tell you, when you start running replay really, really slow, you get a little bit of distortion in there as well, so you've gotta be cognizant to that," suggesting that looking more closely may bring us further from the truththe ball was given to Virginia, the underlying logic being that the most important thing is to get the call right. Is it? What about the flow of the game, the sanity of the viewer, the unspoken understandingsI knocked it out; it's your ballthat run between players and fans, deepening the sport?

This, I will always believe, is the good stuff. Even Bostromwho is so technical that he at one point connects sports fandom to ancient Greek war and says, "You can speculate that, from an evolutionary point of view, being able to detect small differences in fitness would be valuable"agrees these intangibles are worth protecting. Even at the cost of, say, letting simulations run wild.

"You can't predict how an actual game will play out just by sort of measuring the circumference of the biceps and the speed on the treadmill of the athletes," Bostrom says. "And I think if you could predict it, in some sense it could reduce interest. It's not the same as seeing the struggle, the human spirit, the grit, the audience cheering them on."

The question, then, is not so much whether replay or sims or any other technical advance are helpful or efficient but whether we have the ability to recognize when they are aiding sports versus when they are harming them, and when the time is right to rein them in.

"Rather than just allowing everything that makes the performance better," Bostrom says, "we should think more about changes that make the game more fun and rewarding for both the players and the audience."

Are we doing this now? It's hard to say. The COVID-19 pandemic is accelerating change and the acceptance of change. It is clouding the rule-changing thought process. Already, long-standing traditions and powerful illusions have been altered across sports. After years of debate within baseball about the designated hitter, it will be implemented leaguewide as part of MLB's plan for a safe return. It is but a footnote to a much more complex story, which is fine. But also, how does the DH protect anybody from the coronavirus?

The NBA's bubble league will introduce its own oddities, though not everyone will be there to experience them firsthand. Several players have already tapped out of the NBA reboot, some fearing the virus, some having tested positive for it, some unwilling to separate from their loved ones. Others are sitting out so they can focus on social justice reform after expressing concerns that basketball could detract from those efforts. For those traveling to Disney World, it will be a lonely undertaking. Players themselves "are not permitted to enter each other's hotel rooms." Card games, if they do occur, will be monitored closely, and decks will be swapped out frequently.

Every league is drawing its own unprecedented game plan. The NFL is planning to cover the seats closest to the sidelines to keep fans away from players (though the league of course will advertise on the tarp). The NHL will reportedly route its action through two hub cities, Toronto and Edmonton. The measures that college sports will need to takeassuming anybody is on campus come Septemberfigure to be the most drastic of all.

Tech innovation will accompany each return: temperature screenings, artificial crowd noise, broadcasting from home. As quarantine warps our collective sense of time, it feels as though we've known these quirks forever. But not long ago they would have seemed quite strange, impossible, unwelcome, like somebody somewhere out there was toying with our settings.

Leo Sepkowitz joined B/R Mag in 2018. Previously, he was a Senior Writer at SLAM Magazine. You can follow him on Twitter: @LeoSepkowitz.

Read this article:
The Future of Sports - Bleacher Report

Read More...

Page 499«..1020..498499500501..510520..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick